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Abstract
Holoprosencephaly (HPE) is a complex brain malformation resulting from incomplete cleavage of
the prosencephalon, occurring between the 18th and the 28th day of gestation and affecting both
the forebrain and the face. It is estimated to occur in 1/16,000 live births and 1/250 conceptuses.
Three ranges of increasing severity are described: lobar, semi-lobar and alobar HPE. Another
milder subtype of HPE called middle interhemispheric variant (MIHF) or syntelencephaly is also
reported. In most of the cases, facial anomalies are observed in HPE, like cyclopia, proboscis,
median or bilateral cleft lip/palate in severe forms, ocular hypotelorism or solitary median maxillary
central incisor in minor forms. These latter midline defects can occur without the cerebral
malformations and then are called microforms. Children with HPE have many medical problems:
developmental delay and feeding difficulties, epilepsy, instability of temperature, heart rate and
respiration. Endocrine disorders like diabetes insipidus, adrenal hypoplasia, hypogonadism, thyroid
hypoplasia and growth hormone deficiency are frequent. To date, seven genes have been positively
implicated in HPE: Sonic hedgehog (SHH), ZIC2, SIX3, TGIF, PTCH, GLI2 and TDGF1. A molecular
diagnosis can be performed by gene sequencing and allele quantification for the four main genes
SHH, ZIC2, SIX3 and TGIF. Major rearrangements of the subtelomeres can also be identified by
multiplex ligation-dependent probe amplification (MLPA). Nevertheless, in about 70% of cases, the
molecular basis of the disease remains unknown, suggesting the existence of several other
candidate genes or environmental factors. Consequently, a "multiple-hit hypothesis" of genetic and/
or environmental factors (like maternal diabetes) has been proposed to account for the extreme
clinical variability. In a practical approach, prenatal diagnosis is based on ultrasound and magnetic
resonance imaging (MRI) rather than on molecular diagnosis. Treatment is symptomatic and
supportive, and requires a multidisciplinary management. Child outcome depends on the HPE
severity and the medical and neurological complications associated. Severely affected children have
a very poor prognosis. Mildly affected children may exhibit few symptoms and may live a normal life.
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Disease name and synonyms
Holoprosencephaly (HPE)
Midline cleft syndrome
DeMyer sequence
Isolated HPE (non syndromic, non chromosomic)
Familial HPE
Arhinencephaly
Cyclopia
Definition
Holoprosencephaly (HPE, MIM 236100) is a complex
human brain malformation resulting from incomplete
cleavage of the prosencephalon into right and left hemi-
spheres, occurring between the 18th and the 28th day of
gestation. Three levels of increasing severity are described
[1]: lobar HPE, where the right and left ventricles are sep-
arated, but with some continuity across the frontal cortex;
semilobar HPE with a partial separation, and the most
severe form, alobar HPE, with a single brain ventricle and
no interhemispheric fissure. Another milder subtype of
HPE called the middle interhemispheric variant (MIHF)
or syntelencephaly, has now been recognized [2,3] (Table
1). There is a continuous spectrum of abnormal separa-
tion of the hemispheres rather than clearly distinct divi-
sion into these three types of malformation [4]. The
forebrain malformations are generally associated with
facial anomalies, ranging from anophthalmia, cyclopia or
proboscis in the most severe cases, to midline cleft lip, a
simple hypotelorism or even no anomalies in the less
severe HPE forms [5,6] (Table 2). The HPE phenotypic
spectrum also encompasses microforms including facial
midline anomalies with a normal brain. This wide spec-
trum can be observed within the same family [7].
HPE is a genetically heterogeneous anomaly and this phe-
notype is known to be part of different syndromes or
chromosomal anomalies.
Epidemiology
Holoprosencephaly is the most common forebrain devel-
opmental anomaly in humans with prevalence of 1/
16,000 in live borns [8-11], an incidence as high as 1:250
in conceptuses [12], and a worldwide distribution. But
considering the advances in neuroimaging with magnetic
resonance imaging (MRI), children with less severe forms,
like the recently described MIHF or lobar forms, who were
undiagnosed, should be now identified leading to an
increasing prevalence of the disease [13].
Clinical description
As mentioned above, HPE is a complex brain malforma-
tion resulting from incomplete cleavage of the prosen-
cephalon, affecting the forebrain. Therefore, clinical
manifestations involve the central nervous system with
possible facial dysmorphism and various complications
[14]. Due to recent molecular data, the HPE phenotypic
spectrum is very large ranging from severe cerebral malfor-
mations to a microform. This latter form can be defined
by MRI normal brain, but with facial anomalies including
ocular hypotelorism, midline cleft lip and/or flat nose.
Nowadays, most of severe HPE cases are detected by sys-
tematic ultrasound scan and MRI during pregnancy. This
prenatal diagnosis often leads to termination of preg-
nancy, after genetic counseling, regarding to the severity
of the malformations. Milder HPE cases or microforms are
usually not available to prenatal diagnosis due to macro-
scopic normal brain. Nevertheless, these children show
clinical spectrum of HPE described below.
In any case, it is important to establish whether the HPE is
an isolated brain malformation or part of a syndrome
with other systemic manifestations (Table 3)[15] to con-
sider genetic counseling.
Anatomical description
The HPE brain malformation is an incomplete cleavage of
the forebrain, with three classical levels of decreasing
severity, alobar, semilobar and lobar, described in the def-
inition and whose anatomic features are given in Table 1.
This classic definition is not ambiguous, but problems are
encountered at less severe ends of the phenotypic spec-
trum, which includes absent olfactory tracts and bulbs
(arrhinencephaly), agenesis of the corpus callosum, hypo-
pituitarism, single maxillary central incisor [16]. Less clas-
sical features were also described associated with HPE
genes like hypoplasia of the pyriform aperture, ocular
anomalies or anomalies of the extremities [7]. Simon et al.
[4] established that the degree of deep gray nuclei non-
separation parallels the degree of hemispheric non-sepa-
ration.
In most of the cases, facial anomalies are observed in HPE.
The severity of facial dysmorphism correlates with the cer-
ebral anomalies in about 80% of the time (Table 2). These
correlations were first given by DeMyer [5] then modified
by several authors [9,17,18]. Less severe facial dysmor-
phism may include hypotelorism, lateral cleft lip, and/or
iris coloboma [19], and sometimes normal faces can be
observed. Some authors suggest following the classifica-
tion modified by Elias et al. [18], in order to take into
account patients with midline defects and a normal or
sub-normal brain development, but this classification is
essentially based on a genetic definition as it concernsOrphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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most of the time members of a family who only share a
mutation with the proband but do not present any brain
MRI anomalies.
Clinical evaluation in HPE children and complications
Children with HPE experience many medical problems
that need to be detected:
Neurological signs
Developmental delay is present in all live born HPE
patients, and seems in agreement with the severity of the
brain malformation. Approximately half of the patients
with HPE develop epilepsy. Hydrocephaly can occur dur-
ing pre- or postnatal development. Many others signs like
mental retardation, hypotonia, weakness, spasticity, dys-
tonia and abnormal movements are described.
Craniofacial malformations
Microcephaly, hypotelorism or hypertelorism, midline or
lateral cleft lip and/or palate, flat nose, iris coloboma, sin-
gle maxillary central incisors and hypoplasia of the pyri-
form aperture are often noticed.
Endocrine disorders
Diabetes insipidus, growth hormone deficiency, adrenal
hypoplasia, hypogonadism, or thyroid hypoplasia are
very frequent in HPE because the midline malformation
affects the development of the hypothalamus and the
pituitary gland.
Oromotor dysfunction
Feeding and swallowing difficulties are frequent and gen-
erally correlate with the grade of HPE, leading to a require-
Table 1: Anatomic classification of HPE -Different levels of severity [1] [6]
ALOBAR (complete) Small single forebrain ventricle
No interhemispheric division
Absence of olfactory bulbs and tracts
Absence of corpus callosum
Non separation of deep gray nuclei
SEMI-LOBAR Rudimentary cerebral lobes
Incomplete interhemispheric division
Absence or hypoplasia of olfactory bulbs and tracts
Absence of corpus callosum
Varying non separation of deep gray nuclei
LOBAR Fully-developed cerebral lobes
Distinct interhemispheric division
Midline continuous frontal neocortex
Absent, hypoplasic or normal corpus callosum
Separation of deep gray nuclei
MIHF Failure of separation of the posterior frontal and parietal lobes
Callosal genu and splenium normally formed
Absence of corpus callosum
Hypothalamus and lentiform nuclei normally separated
Heterotopic gray matter
Table 2: "The face often predicts the brain" [5, 110]. Parallelism of face and brain phenotypes generally observed in HPE.
Group Morphology HPE degree
(I) Cyclopia Single or double eye
Proboscis
Alobar
(II) Ethmocephaly Distinct sockets
Extreme ocular hypotelorism
Proboscis
Alobar
(III) Cebocephaly Ocular hypotelorism
Proboscis, with single nostril
Alobar
(IVA) Ocular hypotelorism
Midline cleft lip
Flat nose
Alobar
or
Semi-lobar
(IVB) Ocular hypotelorism
Midline cleft lip (complete or partial)
Flat nose
Semi-lobar
or
lobarOrphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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ment for gastrostomy tubes in about two thirds of patients
with alobar or semilobar HPE [13]. These complications
can be due to axial hypotonia, cleft lip and/or palate, gas-
tro esophageal reflux, choking, slowness in eating and fre-
quent pauses and often lead to failure to thrive.
Dysautonomic dysfunction
Instability of temperature, heart and/or breath rate.
Prognosis
It is clear that neurodevelopmental outcome and mortal-
ity risk depend on the severity of HPE. Reports from the
"Carter Centers for Brain Research in Holoprosencephaly
and Related Malformations" (a national North American
consortium funded by a not-for-profit foundation) on 83
children [20-22] and from Rennes (France) on 47 chil-
dren [7] summarized some of the clinical problems and
neurological disorders observed in HPE children. In these
two series, less than half of the children had semilobar
HPE; approximately 15% each had alobar, lobar or MIHF
in the American series, while these forms represented
respectively 17.8%, 27.3% and 17% in the French series.
It is generally reported that HPE children do not survive
beyond early infancy [13,23], but this is essentially true
for severe forms of HPE associated with severe craniofacial
anomalies like cyclopia or ethmocephaly or chromo-
somal anomalies. A retrospective study of perinatal risk
factors of 104 children living with HPE (Carter Center),
performed by Stashinko et al. [24], showed that the mean
age was 4 years and 15% of these children were between
10 and 19 years of age. In this case, children had normal
vision and hearing, and could memorize in spite of their
mental delay [11,25-27].
This underscores the importance of the Carter Neurocog-
nitive Assessment, a new specific evaluation tool designed
for children with HPE [28] and an accurate neuroradio-
logic classification of HPE [13] to help physicians and
families in determining that outcome. Recently, a positive
correlation was found out between the degree of non sep-
aration of the deep grey nuclei and expressive speech skills
[20] but none regarding social awareness, visual attention
and auditory comprehension [29].
However, the prognosis in Holoprosencephaly depends
also on its etiology and is much poorer for those with
cytogenetic abnormalities, with only 2% surviving
beyond one year [11].
Etiology
The etiology of HPE is very heterogeneous. First, this
pathology can be caused by environmental or metabolic
factors. The only formally recognized environmental fac-
tors are insulin-dependent diabetes mellitus (1% risk of
HPE) [30] and maternal alcoholism with a risk that cumu-
lates with smoking (RR 1.4) [31]. HPE in humans has also
been noted in association with prenatal exposure to drugs
(retinoic acid, cholesterol biosynthesis inhibitors [32] or
to infections (cytomegalovirus [33,34], toxoplasma
[35,36], rubella [36,37]). The OMIM classification shows
that HPE can also be associated in about 25% of the cases
with several defined multiple malformation syndromes
with a normal karyotype, like Smith-Lemli-Opitz [38],
Table 3: Syndromic HPE with normal karyotype
Syndromic HPE with normal karyotype
214800 CHARGE syndrome gene CHD7 8q12
146510 Pallister Hall gene GLI3 7p13
270400 Smith Lemli Opitz DHCR7 11q12-q13
180849 Rubinstein-Taybi gene CREBBP 16p11.3
249000 Meckel syndrome
264480 Pseudotrisomy 13
192430 Velo cardio facial Synd gene TBX1 22q11.2
300073 HPE and fetal akynesia, X linked?
300571 HPE, ectrodactyly, cleft lip/palate, X linked?
300373 Osteopathia striata with cranial sclerosis Xp11.4-p11.22
245552 Lambotte syndrome
184705 Steinfeld Syndrome
601357 HPE, amelia, facial cleft
600674 Microtia-anotia
236680 Hydrolethalus syndrome
206900 Microphtalmia syndromic
156810 MLRD association
202650 Dysgnathia complex
601370 Genoa SyndromeOrphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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Pallister Hall [39] or velo-cardio-facial syndrome [40]
(Table 3).
HPE can be due to chromosomal abnormalities, with a
higher prevalence observed in trisomy 13 (70%), trisomy
18 and triploidy. Analysis of recurrent chromosomal
anomalies led to the identification of 12 candidate
regions (named HPE1 to HPE12) on 11 chromosomes
that may contain genes involved in HPE [41]. Large dele-
tions involving HPE loci, like HPE3, are responsible for
contiguous genes syndromes (e.g. del 7qter, Currarino
syndrome).
Finally, HPE may be a solitary manifestation (neither
chromosomal nor syndromic) and several genes are
implicated in this isolated form of HPE.
Genetics of isolated HPE
1) Mode of transmission
This pathology was first described as autosomal dominant
(MIM# 142945), with an incomplete penetrance and a
variable expression [42]. The penetrance in autosomal
dominant HPE is estimated to be 80%, but recent data
also suggest a multigenic and multihit origin [43].
2) Genes
The first genes positively implicated in HPE were identi-
fied from recurrent chromosomal rearrangements. Other
genes were described by studying the SHH signaling path-
way actors or the Nodal/TGFβ pathway, summarized in
Figure 1.
Sonic hedgehog(SHH)  (MIM# 600725; 7q36; HPE3)
[44,45]
SHH was isolated from the human critical region HPE3
on chromosome 7q36. It plays a critical role in early fore-
brain and central nervous system development. SHH is
expressed in the human embryo in the notochord, the
floorplate of the neural tube, the posterior limb buds and
the gut [46]. The SHH protein is a secreted intercellular
signaling molecule, which is synthesized as a precursor
that undergoes autocatalytic cleavage into N-terminal
domain (SHH-N) and C-terminal domain (SHH-C). Dur-
ing the autoprocessing reaction, a cholesterol moiety is
covalently attached to the C-terminus of SHH-N [47].
Mouse and chicken embryos cultured in vitro and exposed
to cyclopamine, an alkaloid blocker of Sonic hedgehog
signaling, exhibit craniofacial anomalies and display phe-
notypes of HPE [48]. Homozygous Shh  mutant mice
present with cyclopia and often die during embryonic
development, whereas the heterozygous mouse appears
normal [49].
SHH is the major gene implicated in holoprosencephaly
(12.7% of HPE cases: 50% of overall point mutations and
38% of overall large deletions) [50,51]. Some of the
mutants were functionally characterized by studying the
production of the active SHH-N fragment and the signal-
ing activity in a reporter cell-based assay [52,53]. In fami-
lies with SHH mutation, an incomplete penetrance and
extremely wide phenotypic variability are observed [7].
Large deletions in 7q36, resulting in the loss of not only
the  SHH  gene but also the HLXB9  gene have been
observed in patients presenting HPE and Curarrino (sacral
agenesia). Nevertheless, one study reported that only 50%
of patients with del(7)(q36), including SHH, have HPE
[43]. HPE can also be caused by apparently balanced
translocations near the SHH  locus, which might be as
much as 200 kb away from the gene, due to position effect
[45].
ZIC2 (MIM# 603073; 13q32; HPE5) [54]
The second gene identified was ZIC2, which encodes a
member of a transcription factor family that includes the
Drosophila odd-paired gene (opa), and contains zinc finger
DNA binding motifs similar to the GLI protein binding
domains. ZIC2 plays an important role in neurulation.
Zic2 knockdown mice show a strong holoprosencephaly
phenotype in which the cerebral hemispheres are fused,
and structures derived from the dorsal midline of fore-
brain are missing or reduced [55].
ZIC2 is the second HPE gene by order of involvement
(9.2% of HPE cases: 31% of overall point mutations and
38% of overall large deletions). Small mutations identi-
fied include a significant part of complex mutations that
are not just base substitutions but up to 30 base-pairs
deletions, insertions or duplications, probably because of
the gene sequence composition. Large deletions in 13q,
including ZIC2, were narrowed by Comparative Genomic
Hybridisation (CGH) array, which allows an inkling of
correlations between the size of the rearrangement and
the phenotype: one fetus with a typical HPE strictly lim-
ited to cerebral anomalies was found to have a deletion of
1, 5 Mb, while another fetus presenting an HPE in a poly-
malformative context carried a 30 Mb deletion.
Most of the time, alterations in ZIC2 correlate with a nor-
mal face and, in some cases, are associated with neural
tube defects or syntelencephaly (MIHF). Spina bifida or
anencephaly have been also described as being associated
with HPE in the same patient or in the same family by sev-
eral authors [7,8,56].
SIX3 (MIM# 603714; 2p21; HPE2) [47]Orphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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SIX3 is an homeobox-containing gene which is homolo-
gous to the Drosophila sine oculis gene; it is involved in
head midline and eye formation.
Mice with reduced levels of Six3 expression present a fail-
ure of forebrain and eye development [57].
Point mutations and large deletions in SIX3 represent 3%
and 1% of HPE cases respectively. They are generally
found in severe phenotypes. New phenotypes like atelen-
cephaly – absence of telencephalon – or syntelencephaly
– failure of separation of the posterior frontal and parietal
right and left lobes [14,58] – may be associated; these
phenotypes can be considered as a continuum of the HPE
spectrum, based on embryological arguments and molec-
ular results involving SIX3 [59].
TGIF (MIM# 602630; 18p11.3; HPE4) [60].
TGIF (TG-interacting factor) is another homeodomain
transcription factor that inhibits signaling through Nodal/
Transforming Growth Factor beta (TGFβ) pathways by
blocking the action of SMAD proteins. Moreover, TGIF is
a repressor of retinoic acid regulated gene transcription
(Figure 1).
Mutations in TGIF account for 1% of studied cases and
large deletions for nearly 1%. These data suggest that TGIF
alterations explain only a very small proportion of HPE
cases, and TGIF involvement in HPE can be discussed
since only 10% of patients carrying a 18p deletion
(including the TGIF  gene) present HPE [61,62] and
mouse models with disrupted entire Tgif do not present
an HPE phenotype [63]. However, recent studies report
Signaling pathways of the main HPE genes or candidate genes Figure 1
Signaling pathways of the main HPE genes or candidate genes. All the parts of these pathways are not necessarily in the same 
tissue or cell type.Orphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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that heterozygous and homozygous deletions of the third
exon of Tgif in mice can result in a defined spectrum of
brain developmental defects including exencephaly,
microcephaly, holoprosencephaly, and abnormalities in
embryonic brain ventricle formation and cleavage [64].
The variable expression observed in families with one
TGIF  mutation makes genotype-phenotype correlations
more difficult: both severe forms and labial/palate cleft
are reported to be associated with mutations in this gene.
Several hypotheses can be produced to explain these
observations. First, it is possible that the TGIF2 gene (in
20q11.2-q12) provides redundancy for TGIF activity in
the forebrain, even if Tgif2 does not have the same activity
as Tgif in the neural tube in chick [65]. Additional studies
will be required to elucidate the role of TGIF in prosen-
cephalic neural development and HPE.
PATCHED1 (MIM# 601309; 9q22) [66]
PATCHED-1 (PTCH) is the receptor for SHH, and nor-
mally acts to repress SHH signaling. This repression is
relieved when SHH binds to PTCH. Four different muta-
tions of the gene were described in five unrelated HPE-
affected individuals. These mutations may affect the abil-
ity of PTCH to bind SHH, or perturb the intracellular
interactions of PTCH with other proteins involved in SHH
signaling. They could subsequently enhance the repressive
activity of PTCH on the SHH pathway and so decrease
SHH signaling.
GLI2 (MIM# 165230; 2q14)
GLI2 is one of three vertebrate transcription factors impli-
cated as obligatory mediators of SHH signal transduction.
Mutations in this gene are preferentially involved in a dis-
tinctive phenotype (within the HPE spectrum) whose
main features include defective anterior pituitary forma-
tion and pan-hypopituitarism [67], not necessarily with
obvious abnormalities of the prosencephalon cleavage.
TDGF1/CRIPTO (MIM# 187395; 3p21.31)
TDGF1 (Teratocarcinoma Derived Growth Factor), also
called CRIPTO, is an EGF-CFC family member and an
obligate co-receptor involved in NODAL signaling, a
developmental program implicated in midline, forebrain,
and left-right axis development in model organisms.
CFC1 (CRYPTIC), another member of this family, has
been demonstrated to be required for proper laterality
development in humans.
Zebrafish rescue assays indicate a role for TDFG1 in mid-
line and forebrain development. One mutation in TDGF1
(3p21.3) has been described in a patient with midline
anomalies of the forebrain [68].
3) Other candidate genes
Numerous candidate loci and candidate genes have been
suggested for HPE (Table 4) (Figure 1). Among these
genes, some were already investigated in HPE.
FOX-H1 (FAST1) (MIM# 603621; 8q24.3) is a co-tran-
scriptional factor of SMAD2 and SMAD4, and intervenes
in TGF-β, activin and nodal signaling pathways. These fac-
tors control early development in vertebrates and are vital
for specification of the anterior-posterior axis. Recent
studies on Fox-H1 null mutant mice showed that embryos
failed to pattern the anterior-posterior axis, form the
node, prechordal mesoderm, notochord and definitive
endoderm. These mutants presented aberrant anterior
head structures and abnormal cardiac development.
Mutations in FOX-H1 in HPE with cardiac malformations
were only described in an abstract [69]; these variants
would affect the DNA-binding domain or the SMAD inter-
acting domain.
The lanosterol synthase gene (MIM# 600909; 21q22.3;
HPE1) is located in the HPE1 critical region, where partial
monosomy 21q was described in several HPE cases (.)
[70-74]. Lanosterol synthase catalyzes a key step in the
biosynthesis of cholesterol, essential in the maturation of
the SHH protein. A previous study reported no mutation
in a small cohort of 30 patients [75], but further investiga-
tions are needed before definitely ruling out this candi-
date.
CFC1 (CRYPTIC) (MIM# 605194; 2q21.1) is a member
of the EGF-CFC family. EGF-CFC genes encode extra cel-
lular proteins that act as essential cofactors for Nodal, a
member of the transforming growth factor beta (TGF-
beta) family, and play key roles in intercellular signaling
pathways during vertebrate embryogenesis (germ-layer
formation, anterior-posterior axis orientation and left-
right axis specification) [76-80]. CFC1 could be consid-
ered as a candidate gene for HPE, even if loss-of-function
mutations in human CFC1 (encoding the CRYPTIC pro-
tein) were identified only in patients with heterotaxic phe-
notypes (randomized organ positioning).
SIL(SCL-interrupting locus) (MIM# 181590; 1p32), was
considered by Karkera et al. [81] as a candidate HPE gene,
as Sil mutants displayed prominent midline neural tube
defects including delay or failure of neural tube closure
and holoprosencephaly. SIL mutations were searched in a
panel of HPE patients, but only several common poly-
morphisms were identified, suggesting that SIL is not a
common factor in HPE pathogenesis in humans.
The human DKK1 gene (MIM# 605189; 10q11.2) was
tested by Roessler et al. [82], as a result of the cyclopiaOrphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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observed in frogs lacking dkk-1. The Dkk gene family has
been recently described as coding for secreted proteins of
a novel class of proteins that act during development to
bind and sequester members of the Bmp and Wnt fami-
lies, establishing developmental zones free of the effects
of these powerful morphogenes [83]. Search for muta-
tions in a cohort of 100 HPE patients revealed four mis-
sense mutations with preserved activity in head induction
assays in frogs, suggesting a limited role for this gene in
HPE pathogenesis.
TMEM1  (Transmembrane protein 1) (MIM# 602103;
21q22.3; HPE1) was designated EHOC-1 for epilepsy,
holoprosencephaly candidate-1 as it was isolated from
contigs of the candidate region HPE1. The protein is pre-
dicted to present multiple putative transmembrane
domains that share partial homology with transmem-
brane proteins including sodium channel proteins [84].
FOXA2 (MIM# 600288; 20p11); in zebrafish, the winged-
helix transcription factor FoxA2 is involved in floor plate
development and differentiation in conjunction with
Cyclops (Nodal) signaling, and FoxA2 may be one com-
ponent of the regulatory circuit controlling expression in
the floor plate [85,86]. Moreover, Collignon et al. [87]
showed that some mice manifest left-right axis malforma-
tions when doubly heterozygous for null mutations in
FoxA2 and in Nodal.
DISP1  (MIM# 607502; 1q42; HPE10) [88-91]. The
encoded protein DISPATCHED (DISP1) presents twelve
transmembrane domains and shares structural homology
with the Patched Drosophila and vertebrates' gene in the
form of a sterol-sensing domain. Disp functions to release
cholesterol-anchored Hh and could be involved in mul-
timeric Shh formation in membrane rafts [92].
EAPP/C14ORF11  (MIM# 609486; 14q13; HPE8) was
defined as a HPE potential candidate gene on chromo-
some 14 [93].
TECT1/TECTONIC (MIM# 609863; 12q24.1). In mouse
embryos, tectonic is expressed in regions that participate
in hedgehog signaling. It is first expressed during gastrula-
tion stages in the ventral node, and then in the gut endo-
derm, limb buds, notochord, somites, neural tube, and
floor plate. Tectonic modulated hedgehog signaling
downstream of smoothened and Rab23, and is required
for maximal hedgehog activation [94].
CHRD (MIM# 603475; 3q27) and NOG (MIM# 602991;
17q22). Chordin is a key developmental protein that dor-
salizes early vertebrate embryonic tissues by binding to
ventralizing TGF-beta-like bone morphogenetic proteins
and sequestering them in latent complexes. Its dorsalizing
effects are counteracted by BMP1 [75,95,96].
The Noggin gene was first discovered as an important fac-
tor in brain and nerve development. The secreted
polypeptide noggin binds and inactivates members of the
TGF-beta superfamily signaling proteins, such as bone
morphogenetic protein 4 [97].
Table 4: Known genes and candidate genes for HPE
LOCI and known HPE genes Candidate genes:
236100 HPE1 21q22.3 Investigated or under investigation
157170 HPE2 2p21 SIX3 600909 LSS 21q22,3 HPE1
142945 HPE3 7q36 SHH 605194 CFC1 2q21.1
142946 HPE4 18p11.3 TGIF 181590 SIL 1p32
609637 HPE5 13q32 ZIC2 605189 DKK1 10q11.2
605934 HPE6 2q37.1–q37.3 Hypothetical
601309 HPE7 9q22.3 PTCH 602103 TMEM1 21q22.3
609408 HPE8 14q prox 600288 FOXA2 20p11
- HPE9 20p13 607502 DISP1 1q42
- HPE10 1q42-qter 609486 EAPP 14q13 HPE8
- HPE11 5pter 609863 TECT1 12q24.1
- HPE12 6q26-qter 603475 CHRD 3q27
600725 gene SHH 7q36 602991 NOG 17q22
602630 gene TGIF 18p11.3 600073 LPR2 2q24–q31
603073 gene ZIC2 13q32 601500 SMO 7q32.2
603714 gene SIX3 2p21 606178 HHIP 4q31.22
187395 gene TDGF1 3p23-p21 112262 BMP4 14q22.2
601309 gene PTCH 9q22 601265 NODAL 10q22.1
603621 gene FOXH1 8q24.3 601366 SMAD2/4 18q21
165230 gene GLI2 2q14 608707 CDO 11q23-q24
605049 TWSG1 18p11.3Orphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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Some chordin/noggin double-null embryos present holo-
prosencephaly, with a single nasal pit, a cyclopic eye, and
agnathia, and resembled embryos lacking sonic hedge-
hog. At embryonic day 12.5, double-mutant embryos
were recovered with more severe phenotypes resembling
aprosencephaly. In double-mutant embryos dissected at
embryonic day 8.5, forebrain reduction was clearly evi-
dent. Chordin and noggin are not necessary for establish-
ing the anterior visceral endoderm but are required for
subsequent elaboration of anterior pattern [98]. BMP
antagonists chordin and noggin compensate for each
other during early mouse development. When both gene
products are removed, antero-posterior, dorso-ventral,
and left-right patterning are all affected.
LPR2 (Low Density Lipoprotein Receptor-Related Protein
2) (MIM# 600073; 2q24–q31) is also called glycoprotein
330 or megalin. Homozygous knockout mice manifest
abnormalities in epithelial tissues [99]. In brain, impaired
proliferation of neuroepithelium produces a holoprosen-
cephalic syndrome, characterized by lack of olfactory
bulbs, forebrain fusion, and a common ventricular sys-
tem.
SMOH (MIM# 601500; 7q32.2)
Smoothened mediate with Patched the cellular response
to the Hedgehog secreted protein signal; the binding of
Sonic hedgehog to its receptor Patched prevents normal
inhibition by PTCH of Smoothened (SMOH).
HHIP  (Human Hedgehog Interacting protein) (MIM#
606178; 4q31.22) is involved in the attenuation of hedge-
hog signaling since ectopic expression of Hip in transgenic
mice results in severe skeletal defects similar to those
observed in Indian hedgehog mutants [100].
BMP4 (MIM# 112262; 14q22.2) is a vital regulatory mol-
ecule that functions throughout development in meso-
derm induction, tooth development, limb formation,
bone induction, and fracture repair. In expression studies
in mouse, it was demonstrated that BMP4 activates the
expression of Msx1, leading to incisor tooth development
[101]. In chick embryos, the first signs of left-right asym-
metry are detected in Hensen's node, essentially by left-
sided Sonic hedgehog expression, and Bmp4 is necessary
to maintain Shh asymmetry within the node [102].
NODAL (MIM# 601265; 10q22.1) is a member of the
TGF-beta gene family and is expressed during mouse gas-
trulation [76]. Nodal has a left-sided expression pattern
that is disrupted in mouse models of LR axis development
[76]. Moreover, Collignon et al. [87] showed that some
mice manifest left-right axis malformations when doubly
heterozygous for null mutations in Nodal and in FoxA2.
SMAD2/4 (MIM# 601366; 18q21). SMAD proteins medi-
ate TGF-beta signaling to regulate cell growth and differ-
entiation. TGF-beta induces activation and nuclear
translocation of SMAD2 which forms complexes with
SMAD4 and regulate transcription of target genes.
CDO/CDON (MIM# 608707; 11q23-24) is another HPE
candidate gene since mice lacking the transmembrane
protein Cdo/Cdon, previously implicated in myogenesis,
display HPE with strain-specific severity and without limb
defects, modeling human HPE and implicating modifier
genes as a cause of variability [103].
The Twisted gastrulation(TWSG 1) gene (MIM# 605049;
18p11.3; HPE4) is located near the TGIF gene. The TWSG
protein is able to either enhance or inhibit signaling by
the bone morphogenetic protein (BMP) subfamily of
TGF-β type factors. All Twsg1 mutant mice, irrespective of
genetic background, exhibit deletions of neural arches in
the cervical vertebrae, and C57BL/6 ones present pro-
nounced forebrain defects including rostral truncations,
holoprosencephaly, cyclopia, agnathia [104].
4) Debate on the multi-hit origin of HPE
HPE seems nowadays to be a multihit pathology, that may
require two or more events involving several genes and/or
environmental factors [43]. Indeed, some of mutations
are found in a heterozygous state with a variable pheno-
typic penetrance in the same family, and double hetero-
zygous mutations have already been identified (in SHH
and in ZIC2 [44], in SHH and in TGIF [61], in GLI2 and
in ZIC2, and two different missense mutations in ZIC2 in
the same fetus. Moreover, a number of HPE cases consist
of an association between several rearrangements detected
by MLPA in different chromosomal regions and, in partic-
ular, a duplication associated with a deletion, like
(7pdup;7qdel) or (8pdup;7qdel)[105]. The finding of
such multiple rearrangements in a same patient suggests a
balanced translocation in one of the normal parents and
reinforces the multigenic and multihit origin. This multi-
hit hypothesis can also offer explanation for the wide phe-
notypic spectrum described for a same mutation in a same
family, the most severe form being due to the additive
effect of several events. This conception can be illustrated
by the finding of a TGIF nonsense mutation in a fetus pre-
senting a semilobar HPE with cebocephaly, turricephaly,
microcephaly and flat face detected by ultrasound, but
also in her father who presented only mild signs like
hypotelorism and lateral cleft lip, although this stop
mutation was predicted to encode a truncated version of
the TGIF protein missing two repression domains [106].
Animal models support this double heterozygosity
hypothesis, since HPE is due to digenic inheritance in
mouse models [43].Orphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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However the number of instances with double hits clearly
identified and confirmed by functional studies remains
relatively restricted to a few cases for the time being,
unlike classic recessive disorders. HPE still behaves as an
apparent autosomal dominant disorder with reduced
penetrance and variable expression, associated with fam-
ily-specific genetic alterations. These deleterious muta-
tions give a susceptibility for developing HPE, upon
which other factors (either genetic either environmental)
modulate expression [107]. The genetic background
would have an influence on the incidence of brain abnor-
malities, as it was described in the mutant mice with dele-
tion of the third exon of Tgif, suggesting that genetic
modifiers functionally interact with the mutant protein
during embryonic brain development [64]. Whether or
not these factors constitute a second hit remains to be
debated.
Diagnostic methods
Based on denaturing high performance liquid chromatog-
raphy (DHPLC) and sequencing, point mutations are
found in the four main HPE genes (SHH, ZIC2, SIX3 and
TGIF) in about 20% of the cases (25% in living children
and 15% in fetuses) [50]; mutations are distributed all
over these genes. Mutations in the 5' regulatory regions of
these genes are also suspected [107] and are under inves-
tigation. All kinds of mutations have been reported but
missense mutations are more frequent than nonsense
ones, which makes the interpretation complex. Whenever
a missense mutation is found, it should be validated using
a functional test suitable for the gene to assess its deleteri-
ous effect on the protein structure and/or function [52].
Recently, gene dosage methods like Quantitative Multi-
plex PCR of Short Fluorescent Fragments (QMPSF) or
Multiplex Ligation Probe Amplification (MLPA) (MRC-
Holland), were added to the molecular diagnosis process
[108]. Large deletions in SHH, ZIC2, SIX3 and TGIF are
found in 8% of the cases (4% in alive children and 12%
in fetuses) [51,109]. While the proportion of point muta-
tions is higher in living children than in fetuses, part of
deletions is, on the contrary, higher in fetuses than in liv-
ing patients, which may explain the more severe pheno-
type in fetuses leading to termination of pregnancy.
A systematic search for gains or losses in the subtelomeres
by MLPA led to the identification of about 4.3% novel
rearrangements involving known but also novel HPE loci.
But, at the moment, this approach still concerns research
field.
These data lead to perform for each patient the successive
molecular tests as described in the algorithm (Figure 2) as
several hits are suspected to induce HPE.
Management including treatment
The care of the child with HPE requires a multidisciplinary
management. This aims to detect complications described
above to avoid an added handicap and improve their
quality of life.
Neurologic complications' management of a child with
HPE is not specific and requires anticonvulsive, physical
and occupational therapies, as for children with other
brain malformations. It is important to consider endo-
crine disorders testing blood and urines samples and look
after dysautonomic dysfunction. Surgery is needed to
repair cleft lip and/or palate.
Genetic counseling and prenatal diagnosis
The severity of HPE requires a genetic counseling, which
is made difficult by the extreme phenotypic variability,
the genetic heterogeneity, the multihit origin and a high
risk of recurrence (13%) in apparently sporadic cases [42].
When a patient presents two associated subtelomeric rear-
rangements and, in particular, duplication associated with
a deletion, it can be inherited from one of the parents car-
rying a balanced translocation, and so far, this could be a
great help in the genetic counseling because of the high
rate of recurrence.
On the contrary, when a mutation is identified in a patient
but is not retrieved in his parents, the HPE onset involves
a de novo mutation, and the recurrence rate cannot be cal-
culated but is lower.
Prenatal ultrasound can detect the central nervous system
and facial abnormalities of severe HPE as early as the first
trimester, but is less sensitive for detection of milder forms
of HPE. Fetal MRI will provide better characterization of
the malformations in the third trimester of the pregnancy.
The greatest care must be taken for molecular prenatal
diagnosis in HPE. Even if a mutation has been identified
and seems to be transmitted with clinical manifestations
in the family, another event, like a mutation in another
gene (not yet identified) or an environmental factor, may
be necessary to generate the holoprosencephaly pheno-
type [43]. In this case, molecular biology performed at the
10–12th week of amenorrhea provides only an additional
criterion with regard to prenatal ultrasound or MRI, which
still takes precedence over molecular analysis. Neverthe-
less, the absence of a familial known mutation in the fetal
DNA may be reassuring, before MRI imaging.
Unresolved questions
When the search for alterations in the four main HPE
genes and the analysis of subtelomeric regions are com-
piled, the combined rate reaches about 33%, so more thanOrphanet Journal of Rare Diseases 2007, 2:8 http://www.OJRD.com/content/2/1/8
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65% of the cases remain unexplained, suggesting the
involvement of many other genes in HPE. The research
project should comprise the search for genomic rearrange-
ments all over the genome, using a pangenomic approach
like CGH array to identify further candidate genes. More-
over, epidemiologic investigations should be done to
check off environmental factors that could act in coordi-
nation with genetic events to give rise to holoprosenceph-
aly.
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